Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ESR1 Gene Mutation”

36 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 36 results

Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Not applicableStudy completedNCT00342498
What this trial is testing

Estrogen Receptor Gene Mutations

Who this might be right for
MutationsHormones
National Institute of Environmental Health Sciences (NIEHS)
Testing effectiveness (Phase 2)Looking for participantsNCT05768139
What this trial is testing

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Who this might be right for
Breast CancerSolid Tumors, Adult
Eli Lilly and Company 720
Testing effectiveness (Phase 2)UnknownNCT03879174
What this trial is testing

Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation

Who this might be right for
Breast Cancer Female
Mediclinic Middle East 25
Early research (Phase 1)Study completedNCT01104259
What this trial is testing

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerHereditary Breast/Ovarian Cancer - BRCA1+6 more
University of Washington 50
Not applicableLooking for participantsNCT06548919
What this trial is testing

Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer

Who this might be right for
ESR1 Gene MutationAdvanced Breast Cancer
SciClone Pharmaceuticals 450
Early research (Phase 1)Ended earlyNCT02476955
What this trial is testing

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Who this might be right for
Solid TumorsOvarian CancerEndometrial Cancer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 41
Early research (Phase 1)Active Not RecruitingNCT02432963
What this trial is testing

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Who this might be right for
Adult Solid NeoplasmBladder CarcinomaColon Carcinoma+14 more
City of Hope Medical Center 11
Large-scale testing (Phase 3)Study completedNCT03079011
What this trial is testing

PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

Who this might be right for
Metastatic Breast Cancer
UNICANCER 1,017
Large-scale testing (Phase 3)Active Not RecruitingNCT06382948
What this trial is testing

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Who this might be right for
Advanced Breast CancerER-positive Breast CancerHER2-negative Breast Cancer+1 more
MedSIR 240
Testing effectiveness (Phase 2)Study completedNCT05054374
What this trial is testing

Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Who this might be right for
Breast CancerBreast Cancer Stage IVHER2-negative Breast Cancer+4 more
Memorial Sloan Kettering Cancer Center 6
Testing effectiveness (Phase 2)Study completedNCT03781063
What this trial is testing

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc. 100
Early research (Phase 1)Looking for participantsNCT05868226
What this trial is testing

PRE-I-SPY Phase I/Ib Oncology Platform Program

Who this might be right for
HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+18 more
QuantumLeap Healthcare Collaborative 124
Large-scale testing (Phase 3)Looking for participantsNCT06065748
What this trial is testing

Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche 1,050
Very early researchStudy completedNCT02913430
What this trial is testing

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

Who this might be right for
Metastatic Breast Cancer
Shannon Puhalla 7
Not applicableUnknownNCT05814224
What this trial is testing

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA

Who this might be right for
Hormone Receptor Positive Breast CarcinomaBreast NeoplasmsNeoplasms, Breast+4 more
Centro di Riferimento Oncologico - Aviano 164
Early research (Phase 1)Study completedNCT01219699
What this trial is testing

BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Who this might be right for
Advanced Solid Tumors With an Alteration of the PIK3CA GeneEstrogen Receptor Positive Breast Cancer
Novartis Pharmaceuticals 221
Not applicableEnded earlyNCT01346579
What this trial is testing

Biomarkers in Tissue Samples From Older Women With Breast Cancer

Who this might be right for
Breast Cancer
Alliance for Clinical Trials in Oncology 505
Testing effectiveness (Phase 2)Looking for participantsNCT07222215
What this trial is testing

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Who this might be right for
Estrogen-receptor-positive Breast CancerMetastatic Breast CancerBreast Cancer+6 more
Kristina A. Fanucci 297
Not applicableTemporarily pausedNCT02993068
What this trial is testing

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Who this might be right for
BARD1 Gene MutationBRCA1 Gene MutationBRCA2 Gene Mutation+12 more
M.D. Anderson Cancer Center 5,200
Load More Results